Sales in the biologics sector show modest but healthy growth rates for the fourth consecutive year, with cancer drugs garnering the greatest revenues. As the diabetes epidemic grows and innovation of insulins continues, drug companies in that space are moving up in the ranks.
IMS Health Top-Line Market Data. <http://www.imshealth.com/portal/site/ims>
Aggarwal, S. What's fueling the biotech engine-2009–2010. Nat. Biotechnol. 28, 1165–1171 (2010).
Aggarwal, S. What's fueling the biotech engine—2008. Nat. Biotechnol. 27, 987–993 (2009).
Aggarwal, S. What's fueling the biotech engine—2010 to 2011. Nat. Biotechnol. 29, 1083–1089 (2011).
Hamlin, P.A. Is maintenance rituximab now ready for PRIMA-time? Curr. Oncol. Rep. 12, 355–357 (2010).
Garber, K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat. Biotechnol. 29, 467–468 (2011).
Sandborn, W.J. et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616–624 (2012).
van Vollenhoven, R.F. et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508–519 (2012).
Helwick, C. Bevacizumab beyond progression prolongs survival in metastatic colorectal cancer. The ASCO Post 3 (15 July 2012).
Heitz, F. et al. Bevacizumab in the treatment of ovarian cancer. Adv. Ther. 29, 723–735 (2012).
Bach, P.B., Saltz, L.B. and Wittes, R.E., “In cancer care, costs matters.” NY Times, 14 October 2012
de Claro, R.A. et al. U.S. Food and Drug Administration approval summary: Brentuximab Vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large cell lymphoma. Clin. Cancer Res. 18, 5845–5849 (2012).
Zinman, B. et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377, 924–931 (2011).
Collins, A.J. ESRD Payment Policy Changes: The New “Bundled” Dialysis Prospective Payment System in the United States (US Renal Data System, 2012). <http://www.usrds.org/2012/pres/USDialysisBundle_impact_NKFCM2012.pdf>
Aggarwal, S. Access, Uptake and Utilization Management of Multiple Sclerosis Products in the United States. Abstract PND72, presented at15th Annual European Congress, November 3–7, 2012, Berlin, Germany.
Hayes, E. Dendreon readies for next Provenge hurdles: supply and reimbursement. The Pink Sheet Daily 71 <http://www.elsevierbi.com/publications/the-pink-sheet/72/018/dendreon-readies-for-next-provenge-hurdles-supply-and-reimbursement> (3 May 2010).
Aggarwal, S. Targeted cancer therapies. Nat. Rev. Drug Discov. 9, 427–428 (2010).
Polonsky, K.S. The past 200 years in diabetes. N. Engl. J. Med. 367, 1332–1340 (2012).
Aggarwal, S. Impact of 2009–2011 global health care reforms on pricing, access and health outcomes strategy. Podium Presentation UT2 presented at International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, June 2–6, 2012, Washington, DC, USA.
SA thanks American Society of Clinical Oncology (ASCO), American College of Rheumatology (ACR), American Association of Liver Diseases (AASLD), American Heart Association (AHA), American Society of Hematology (ASH) and Biotechnology Industry Association (BIO) for providing support for this article.
About this article
Cite this article
Aggarwal, S. What's fueling the biotech engine—2011 to 2012. Nat Biotechnol 30, 1191–1197 (2012). https://doi.org/10.1038/nbt.2437
Electrostatically Mediated Protein-Protein Interactions for Monoclonal Antibodies: A Combined Experimental and Coarse-Grained Molecular Modeling Approach
Journal of Pharmaceutical Sciences (2019)
Biotechnology and Bioengineering (2018)